10. FDA granted accelerated approval to polatuzumab vedotin in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies in june 2019. What is MOA of polatuzumab vedotin ?